File Download
  Links for fulltext
     (May Require Subscription)

Conference Paper: Bevacizumab after cetuximab failure in Kras wild-type metastatic colorectal carcinoma

TitleBevacizumab after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
Authors
KeywordsMedical sciences
Oncology
Issue Date2012
PublisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/
Citation
The 14th World Congress of the European Society for Medical Oncology (ESMO) on Gastrointestinal Cancer, Barcelona, Spain, 27–30 June 2012. In Annals of Oncology, 2012, v. 23 suppl. 4, p. iv100-iv101, abstract P-0248 How to Cite?
AbstractINTRODUCTION: Bevacizumab and cetuximab both improve treatment efficacy when given with chemotherapy for metastatic colorectal carcinoma (mCRC) in both first-and second-line setting. Cetuximab has enhanced efficacy in Kras wild-type tumor. However, inferior outcomes were reported in two phase III randomised controlled trials for the concurrent use of bevacizumab and cetuximab with chemotherapy. There is an urgent need to define the optimal sequence of use of these two agents. With regard to the pre-clinical data that increased VEGF expression is associated with acquired resistance to anti-EGFR antibody, we performed a retrospective analysis on the outcomes of patients who received bevacizumab-containing …
DescriptionPosters: P-0248
Persistent Identifierhttp://hdl.handle.net/10722/160413
ISSN
2015 Impact Factor: 9.269
2015 SCImago Journal Rankings: 4.362

 

DC FieldValueLanguage
dc.contributor.authorLam, KOen_US
dc.contributor.authorLee, Ven_US
dc.contributor.authorChoi, CWen_US
dc.contributor.authorLiu, RKYen_US
dc.contributor.authorLeung, TWen_US
dc.contributor.authorKwong, DLWen_US
dc.date.accessioned2012-08-16T06:10:16Z-
dc.date.available2012-08-16T06:10:16Z-
dc.date.issued2012en_US
dc.identifier.citationThe 14th World Congress of the European Society for Medical Oncology (ESMO) on Gastrointestinal Cancer, Barcelona, Spain, 27–30 June 2012. In Annals of Oncology, 2012, v. 23 suppl. 4, p. iv100-iv101, abstract P-0248en_US
dc.identifier.issn0923-7534-
dc.identifier.urihttp://hdl.handle.net/10722/160413-
dc.descriptionPosters: P-0248-
dc.description.abstractINTRODUCTION: Bevacizumab and cetuximab both improve treatment efficacy when given with chemotherapy for metastatic colorectal carcinoma (mCRC) in both first-and second-line setting. Cetuximab has enhanced efficacy in Kras wild-type tumor. However, inferior outcomes were reported in two phase III randomised controlled trials for the concurrent use of bevacizumab and cetuximab with chemotherapy. There is an urgent need to define the optimal sequence of use of these two agents. With regard to the pre-clinical data that increased VEGF expression is associated with acquired resistance to anti-EGFR antibody, we performed a retrospective analysis on the outcomes of patients who received bevacizumab-containing …-
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/en_US
dc.relation.ispartofAnnals of Oncologyen_US
dc.subjectMedical sciences-
dc.subjectOncology-
dc.titleBevacizumab after cetuximab failure in Kras wild-type metastatic colorectal carcinomaen_US
dc.typeConference_Paperen_US
dc.identifier.emailLam, KO: lamkaon@hku.hken_US
dc.identifier.emailLee, V: vhflee@hku.hken_US
dc.identifier.emailLiu, RKY: ricoliu@hkucc.hku.hken_US
dc.identifier.emailLeung, TW: ltw920@hkucc.hku.hken_US
dc.identifier.emailKwong, DLW: dlwkwong@hku.hken_US
dc.identifier.authorityLam, KO=rp01501en_US
dc.identifier.authorityLee, V=rp00264en_US
dc.identifier.authorityKwong, DLW=rp00414en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1093/annonc/mds153-
dc.identifier.hkuros205048en_US
dc.identifier.volume23en_US
dc.identifier.issuesuppl. 4-
dc.identifier.spageiv100, abstract P-0248en_US
dc.identifier.epageiv101en_US
dc.publisher.placeUnited Kingdom-
dc.customcontrol.immutablesml 140206-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats